Alumis: Bullish Hype Masks Real Risks Ahead of Key Catalysts

What happened

Alumis has received a renewed Buy rating driven by upcoming data catalysts for envudeucitinib, but the DeepValue analysis cautions that the stock's ~$2.5B valuation already prices in approval and commercial success. Despite strong Phase 3 psoriasis data, envudeucitinib's twice-daily dosing and fierce competition from once-daily rivals like Takeda's zasocitinib and J&J's icotrokinra limit its upside. The company's annualized cash burn of ~$400M and recent dilutive equity raise further strain the risk/reward profile. Upcoming catalysts, including long-term psoriasis data, NDA submission, and pivotal SLE data in 2H26, could either validate or undermine the current valuation. Investors should remain cautious, as the margin of safety is thin and the story is already crowded.

Implication

At $2.5B, Alumis prices in a smooth approval and significant market share, but the competitive landscape and binary lupus data create asymmetric downside. We recommend reducing exposure near $24 and waiting for a better entry near $17, where the risk/reward becomes more favorable.

Thesis delta

The market has embraced the bullish narrative following strong Phase 3 data, but the DeepValue report's 'potential sell' rating highlights that the stock's valuation leaves little room for error. The key shift is that near-term catalysts are now skewed toward risk rather than reward, as long-term safety, dosing convenience, and lupus efficacy remain unproven. This warrants a more defensive stance until incremental data confirm superiority over oral competitors.